As CAR-T therapies continue to evolve, improved care coordination, earlier patient referrals and enhanced support systems can ...

Fate Therapeutics announced promising preliminary clinical trial results for FT819, an investigational CAR T-cell therapy for ...

Kreitman of the National Cancer Institute has spent more than three decades working on hairy cell leukemia (HCL). He first encountered the disease in 1983 as a medic ...

For patients with hairy cell leukemia whose cancer returns after multiple treatments, researchers are investigating whether ...

An experimental cancer treatment has shown promising early results in patients whose tumours no longer respond to standard ...

Mouse experiments show that CD4+ T cells license CD8+ T cells through CD40 signaling, enabling combination immunotherapy to ...

Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...

Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment ...

Octane Biotech Inc. (“Octane”) and Currus Biologics (“Currus”), an Australian biotech developing the BEAT, a proprietary, universal, bispecific antibody platform to unlock CAR T-cell therapy for solid ...

Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) show a ...

New research led by the University of Colorado Anschutz is offering hope to people living with stiff person syndrome (SPS), ...

A published case report describes a woman whose EBV-positive NK/T-cell lymphoma relapsed inside her eye and later involved ...